Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Daboia siamensis factor X activator metalloproteinase (RVV-X) is a potent procoagulant enzyme found in the venom of the Eastern Russell's viper (Daboia siamensis). It is a heterotrimeric P-IIIc snake venom metalloproteinase (SVMP) composed of a catalytic heavy chain containing metalloproteinase, disintegrin-like, and cysteine-rich domains, and two C-type lectin-like light chains (UniProt: P0C2P1, P0C2P2, P0C2P3; PubMed: 23567015). The enzyme's primary biological function is the highly specific activation of blood coagulation Factor X into Factor Xa by cleaving the Arg194-Ile195 bond in the Factor X heavy chain (PubMed: 11469735). This activation occurs independently of the physiological tenase complex (Factor VIIIa/IXa) and calcium ions, leading to rapid and uncontrolled thrombin generation. Clinically, this results in venom-induced consumptive coagulopathy (VICC), a life-threatening condition characterized by the depletion of clotting factors, such as fibrinogen, and systemic hemorrhage (WHO Snakebite Guidelines; PubMed: 30114433). RVV-X is a primary target for neutralization by therapeutic antivenoms, and research is ongoing into small-molecule inhibitors like DMPS (dimercapto-1-propanesulfonic acid) and marimastat to mitigate its enzymatic activity in the field (PubMed: 32503855). Additionally, it serves as a critical reagent in diagnostic assays such as the Dilute Russell's Viper Venom Time (dRVVT) used to detect lupus anticoagulants and assess Factor X deficiency (StatPearls: Lupus Anticoagulant).
Therapeutic agents target this molecule through antibody-mediated neutralization (antivenom) or by chelating the essential zinc ion in the metalloproteinase catalytic site, thereby preventing the proteolytic activation of Factor X.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Daboia siamensis factor X activator metalloproteinase (RVV-X) (RVV-X).